Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Body hair

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Body hair. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-002833-19 Sponsor Protocol Number: SPD488-402 Start Date*: 2006-10-12
    Sponsor Name:Shire Pharmaceutical Development
    Full Title: A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)
    Medical condition: Excessive facial hair in females (Facial hirsutism)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020112 Hirsutism LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000613-22 Sponsor Protocol Number: CO-150225133959-HRCT Start Date*: 2018-10-15
    Sponsor Name:Johnson & Johnson Consumer Inc
    Full Title: A 16 Week, Single-center, Randomized, Placebo- and Active-controlled Proof of Principle Study to Assess the Efficacy and Safety of a 5% Minoxidil Topical Gel Formulation in Male subjects with Andro...
    Medical condition: Alopecia Androgentica
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001714-14 Sponsor Protocol Number: B7981015 Start Date*: 2019-07-22
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR...
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005573-36 Sponsor Protocol Number: DC0120LE202 Start Date*: 2015-06-18
    Sponsor Name:Pierre Fabre Dermatologie represented by the Institut de Recherche Pierre Fabre (IRPF)
    Full Title: Assessment of the efficacy of a new formulation of minoxidil (DC120) on hair growth, in a minizone model in androgenetic alopecia in men
    Medical condition: androgenetic alopecia
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004651-36 Sponsor Protocol Number: GlibforCS Start Date*: 2021-05-21
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Glibenclamide Treatment for Cantú syndrome
    Medical condition: Cantú syndrome
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005640-14 Sponsor Protocol Number: 42994 Start Date*: 2013-04-15
    Sponsor Name:Erasmus MC
    Full Title: The effects of hormonal contraception on the HPA-axis functioning
    Medical condition: healthy female volunteers; hormonal contraception method used: combined method (oestrogens en progestins) and progesterone-only method.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10010812 Contraceptive methods female HLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002179-91 Sponsor Protocol Number: MLE4901-101 Start Date*: 2017-01-17
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)
    Medical condition: Polycystic Ovary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013275-21 Sponsor Protocol Number: 05-2009 Start Date*: 2009-12-03
    Sponsor Name:Imperial College Healthcare NHS Trust
    Full Title: Pilot Study: Evaluating the effect of 300microgram testosterone patches in addition to Hormone Replacement Therapy on arterial compliance, insulin resistance and sexual desire
    Medical condition: Arterial compliance Insulin sensitivity Decreased sexual desire after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020112 Hirsutism LLT
    9.1 10001763 Alopecia, reversible LLT
    9.1 10000496 Acne LLT
    9.1 10059294 Oily skin LLT
    9.1 10028813 Nausea LLT
    9.1 10040880 Skin irritation LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005911-25 Sponsor Protocol Number: 001 Start Date*: 2008-10-10
    Sponsor Name:Imperial College Healthcare NHS Trust
    Full Title: A randomised, placebo controlled, double blind study to evaluate the effect of 300mcg testosterone patches in addition to HRT on arterial compliance, insulin resistance and sexual desire.
    Medical condition: - arterial compliance - insulin resistance - decreased sexual desire after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020112 Hirsutism LLT
    9.1 10001763 Alopecia reversible LLT
    9.1 10000496 Acne LLT
    9.1 10059294 Oily skin LLT
    9.1 10028813 Nausea LLT
    9.1 10040880 Skin irritation LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-020206-14 Sponsor Protocol Number: 09.0058 Start Date*: 2011-01-31
    Sponsor Name:St George's University of London
    Full Title: Evaluation study of Meticillin Resistant Staphylococcus aureus (MRSA) during routine nasal decolonisation programmes with Bactroban Nasal® ointment, Chlorhexidine Gluconate 4% body and hair wash, a...
    Medical condition: MRSA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005466-19 Sponsor Protocol Number: R0002198 Start Date*: 2014-05-26
    Sponsor Name:RadboudUMC
    Full Title: Cytokine inhibition in Chronic Fatigue Syndrome patients - a pilot study.
    Medical condition: Chronic Fatigue Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003688-24 Sponsor Protocol Number: P12.??? Start Date*: 2012-12-12
    Sponsor Name:Leiden University Medical Center
    Full Title: Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290
    Medical condition: Complex regional pain syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003212-22 Sponsor Protocol Number: 10MI30 Start Date*: 2013-06-03
    Sponsor Name:GOSH/ICH Joint Research & Development Office
    Full Title: Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome
    Medical condition: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002720-24 Sponsor Protocol Number: EXP-1377 Start Date*: 2017-10-17
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a
    Medical condition: Alopecia Areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005627-32 Sponsor Protocol Number: IIVOP Start Date*: 2014-06-12
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study
    Medical condition: Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003210-39 Sponsor Protocol Number: SXR001 Start Date*: 2021-11-23
    Sponsor Name:Sixera Pharma
    Full Title: A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-in-man (FTIM) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applie...
    Medical condition: Netherton-syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001020-36 Sponsor Protocol Number: MS301 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI...
    Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001001-28 Sponsor Protocol Number: G200501 Start Date*: 2006-05-04
    Sponsor Name:GTx Inc
    Full Title: Double-blind, placebo controlled, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of GTx-024 in Postmenopausal Females and Elderly Males
    Medical condition: Healthy volunteers (Postmenopausal Females and Elderly Males)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002073-60 Sponsor Protocol Number: Start Date*: 2012-11-30
    Sponsor Name:University of Warwick
    Full Title: Liraglutide in PCOS (LIPOS) Study: Evaluation of the Efficacy of Liraglutide on Menstrual Cyclicity in Women with PCOS - a prospective randomised double-blind placebo-controlled study
    Medical condition: Polycystic ovary syndrome (PCOS).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002394-59 Sponsor Protocol Number: P142 Start Date*: 2020-11-30
    Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital
    Full Title: Medical Cannabis for fibromyalgia - The CANNFIB trial Protocol for a randomized, double-blind, placebo-controlled, parallelgroup, single-center trial
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 21:26:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA